CONDENSED CONSOLIDATED BALANCE SHEETS $ in Thousands	3 Months Ended	5 Months Ended	6 Months Ended
	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2024 USD ($)
Current assets:
Cash and cash equivalents	$ 3,442	$ 5,158	$ 3,442
Prepaid expenses and other current assets	577	1,064	577
Total current assets	4,019	6,222	4,019
Property and equipment, net	282	332	282
Operating lease right-of-use asset	1,404	262	1,404
Other assets	29	29	29
Total assets	5,734	6,845	5,734
Current liabilities:
Accounts payable	3,030	3,388	3,030
Accrued clinical trials expenses	2,333	5,128	2,333
Accrued compensation	1,248	943	1,248
Other accrued expenses	3,818	3,590	3,818
Total current liabilities	10,429	13,049	10,429
Convertible notes at fair value, including related party amount of $13,292 and $0, at June 30, 2024 and December 31, 2023, respectively	13,292		13,292
Operating lease liability	1,262		1,262
Warrant liability	1,467	1,447	1,467
Contingent consideration liability	6,886	104,350	6,886
Embedded forward purchase agreements and derivative liabilities	345	41,043	345
Total liabilities	33,681	159,889	33,681
Commitments and contingencies
Stockholders' Deficit:
Class A common stock, $0.0001 par value; 500,000,000 shares authorized at June 30, 2024 and December 31, 2023, and 39,122,238 and 37,159,600 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	4	4	4
Additional paid-in capital	399,557	381,264	399,557
Subscription receivables		(60,710)
Accumulated deficit	(427,508)	(473,602)	(427,508)
Total stockholders' deficit	(27,947)	(153,044)	(27,947)
Total liabilities and stockholders' deficit	$ 5,734	$ 6,845	$ 5,734
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor	Successor